https://www.selleckchem.com/products/arv-110.html
During cancer cachexia, both skeletal muscle and adipose tissue losses take place. The use of β2-agonists, formoterol in particular, has proven to be very successful in the treatment of the syndrome in pre-clinical models. The object of the present research was to study the effects of a combination of formoterol and dantrolene, an inhibitor of the ryanodine receptor 1 (RyR1), on body weight loss and cachexia in tumour-bearing animals. Rats were separated into two groups controls (C) and tumour bearing (T. TB group was further subdivid
Like
Comment
Share
